Skip to content

Search

Funding

The Centre is committed to supporting high quality research by providing support for researchers to undertake activities of high priority to the WCVID.

2021 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful recipients for the 2021 Round 2 Seed Funding Grants. Julie Hibbert | Validating a

2017 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2017 Round 2 Wesfarmers Centre Seed Funding. The Wesfarmers Centre

2017 Round 1 Seed Funding Recipients

Congratulations goes to Dr Asha Bowen and Dr Ruth Thornton for being the successful first round recipients of the WCVID.

2016 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2016 Round 2 Wesfarmers Centre Seed Funding.

2015 Seed Funding Recipients

Eight applicants were successful, and were awarded $15,000 each for activities supporting subsequent research grant applications.

2014 Seed Funding Recipients

In 2014, the Wesfarmers Centre of Vaccines & Infectious Diseases put out a first call for seed funding proposals.

Spritz-OM

Preventing over half of the world’s ear infections with a therapy such as Spritz-OM will significantly improve health and educational outcomes on a global scale.

Excess respiratory mortality and hospitalizations associated with influenza in Australia, 2007-2015

Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.

Echinocandins in Pediatric Invasive Candidiasis and the Challenges of Antifungal Use in Children

In pediatric invasive candidiasis (IC), epidemiology and risk factors differ compared to adults. Furthermore, the use of antifungals in children is challenging and requires consideration of availability and tolerability of formulations, pharmacokinetic and pharmacodynamic variations, and safety in different age groups.